Cancer
eTheRNA awarded €6.9 million TIGER Grant by European Commission
March 22, 2021Sales and Marketing Cancer, EU
eTheRNA immunotherapies, a clinical-stage company, has been awarded a grant of €6.9 million by the European Commission to develop a …
Antion launch new technology for cancer and tumour treatments
March 18, 2021Cancer, action, blood cancer, myeloma
Antion Biosciences has launched a new T-cell technology platform to help with the development of new curative therapies for diseases …
PEP-Therapy and Institut Curie’s cancer drug trial approved in France
March 17, 2021Research and Development Cancer, France, Pep-therapy
PEP-Therapy and Institut Curie have been granted approval from the French National Agency for Medicines and Health Products (ANSM) to …
Phase III trial of Libtayo stopped early after positive overall survival results
March 15, 2021Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi
A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …
Complix and I-Mab sign deal to develop alphabody cancer therapies
March 11, 2021Cancer, Complix, oncology
Biopharmaceutical company Complix has signed a drug discovery deal with I-Mab Biopharma, a clinical-stage company focused on the discovery, development, …
Lilly’s cancer drug Retsevmo gets UK approval for multiple indications
March 10, 2021Research and Development Cancer, Eli Lilly, MHRA
The MHRA has granted conditional marketing authorisation for Eli Lilly’s Retsevmo (selpercatinib) as monotherapy for a number of cancer indications.
Novartis’ canakinumab fails to improve lung cancer survival in Phase III study
March 9, 2021Manufacturing and Production Cancer, Novartis, lung cancer
Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …
Roche voluntarily withdraws Tecentriq’s US bladder cancer indication
March 8, 2021Sales and Marketing Cancer, Roche, bladder cancer, tecentriq
Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …
Amgen to acquire Five Prime Therapeutics for approximately $1.9bn
March 5, 2021Medical Communications Amgen, Cancer, five prime
Amgen has announced it will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of …
Hong Kong Baptist University researchers develop drug for EBV-associated cancers
March 4, 2021Cancer, Epstein-barr virus, Hong Kong
Researchers at Hong Kong Baptist University have developed a novel drug with the potential to become a next-generation treatment for …
Cancer Research UK joins forces with Teon to develop new cancer drug
March 2, 2021Manufacturing and Production Cancer, Cancer Research UK, Teon
Cancer Research UK and Teon Therapeutics have entered a collaboration agreement to progress the early phase clinical development of Teon’s new cancer drug. The partnership …
Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal
March 1, 2021Sales and Marketing Cancer, Kazia, Oasmia
Oasmia Pharmaceutical, an innovation-focused specialty pharmaceutical company, is set to acquire exclusive global development rights for Kazia Therapeutics’ ovarian cancer …
Ipsen receives CHMP recommendation for Cabometyx in combination with Opdivo
March 1, 2021Sales and Marketing Cancer, EMA, ipsen
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Ipsen’s Cabometyx (cabozantinib) in combination with …
NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer
February 26, 2021Medical Communications Cancer, NICE, Novartis
NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …
New research article confirms role of masitinib as a potential pancreatic cancer therapy
February 25, 2021AB Sciences, Cancer, masitinib
A recently published, peer-reviewed research article has concluded that the inhibition of mast cells with AB Science’s masitinib could represent …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
